PLG-007 and Its Active Component Galactomannan-α Competitively Inhibit Enzymes That Hydrolyze Glucose Polymers

PLG-007 is a developmental therapeutic compound that has been clinically shown to reduce the magnitude of postprandial glucose excursions and has the potential to be an adjunct treatment for diabetes and inflammatory-related diseases. The present investigation is aimed at understanding the molecular...

Descripción completa

Detalles Bibliográficos
Autores principales: Miller, Michelle C., Dregni, Aurelio J., Platt, David, Mayo, Kevin H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9316267/
https://www.ncbi.nlm.nih.gov/pubmed/35887087
http://dx.doi.org/10.3390/ijms23147739

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9316267/
https://www.ncbi.nlm.nih.gov/pubmed/35887087
http://dx.doi.org/10.3390/ijms23147739

Ejemplares similares